Giant axonal neuropathy (GAN) is a progressive neurodegenerative disease caused by autosomal recessive mutations in the GAN gene resulting in a loss of a ubiquitously expressed protein, gigaxonin. Gene replacement therapy is a promising strategy for treatment of the disease; however, the effectiveness and safety of gigaxonin reintroduction have not been tested in human GAN nerve cells. Here we report the derivation of induced pluripotent stem cells (iPSCs) from three GAN patients with different GAN mutations. Motor neurons differentiated from GAN iPSCs exhibit accumulation of neurofilament (NF-L) and peripherin (PRPH) protein and formation of PRPH aggregates, the key pathological phenotypes observed in patients. Introduction of gigaxonin either using a lentiviral vector or as a stable transgene resulted in normalization of NEFL and PRPH levels in GAN neurons and disappearance of PRPH aggregates. Importantly, overexpression of gigaxonin had no adverse effect on survival of GAN neurons, supporting the feasibility of gene replacement therapy. Our findings demonstrate that GAN iPSCs provide a novel model for studying human GAN neuropathologies and for the development and testing of new therapies in relevant cell types. † Present address:
Introduction
Disorganization of the neurofilament (NF) network is a feature of several neurodegenerative disorders, including amyotrophic lateral sclerosis, Parkinson's disease and axonal Charcot-MarieTooth disease (1, 2) . Patients with giant axonal neuropathy (GAN) provide a particularly striking example: peripheral nerve biopsies show accumulations of NFs within enlarged axons (3) , while the intermediate filament desmin is seen to accumulate in muscle fibers, glial fibrillary acidic protein in astrocytes and vimentin in multiple cell types, including primary fibroblast biopsies from patients (4, 5) . Patients with GAN present in their first decade with loss of motor and sensory function. Currently, there is no treatment for GAN, and the life expectancy is typically <30 years. Whether NF accumulation in neurons contributes directly to the pronounced sensory and motor neuropathy that is a clinical hallmark of GAN is not known, but pathological observations of axonal loss, enlarged axons with abnormally thin myelin sheaths, atrophy of the pyramidal tracts, swelling of some axons in the spinal roots and anterior horn cell loss in the cervical and lumbar regions of the spinal cord would be consistent with a causal role (6) (7) (8) (9) . GAN is a rare autosomal recessive disease caused by mutations in a single gene, GAN, which encodes gigaxonin, a ubiquitously expressed cytoplasmic protein that has been postulated to act as an E3 ligase substrate adaptor (10) . To model GAN pathology in the mouse, two loss-of-function approaches were explored: deletion of either the promoter-exon1 region or exons 3-5. The former did not develop any overt neurological defects over 15 months (11) . The latter strategy was adopted for three GAN Δex3-5 models. The first, published by Ding et al. (12) , was reported to develop strong motor deficits as early as 6 months of age, but the characterization was performed using a heterogeneous genetic background (11) . Subsequently, GAN Δex3-5 models were made on pure 129/SvJ and C57BL/6 backgrounds, respectively (13) . Despite the detectable accumulation of intermediate filaments and the absence of gigaxonin at 48 weeks of age, the former model shows only a mild motor impairment from 60 weeks onward and the latter a mild sensory impairment (13) . The relatively mild sensorimotor phenotype seen in both cases raises the possibility that gigaxonin engages in species-specific interactions and functions that might more faithfully be modeled using human cells. Mouse and human gigaxonin share 98% similarity, with amino acid variants in the BR-C, ttk and bab (BTB), BTB and Cterminal Kelch (BACK) and Kelch domains. It is unknown what effect, if any, these amino acid variants have on the structure and function of human and mouse gigaxonin. Successful derivation of induced pluripotent stem cells (iPSCs) (14, 15) from patient skin fibroblasts provides an opportunity to model the pathogenesis and treatment of human heritable diseases in cell culture (16) (17) (18) (19) (20) (21) . Given the inaccessibility of primary human neurons, iPSCs present an appealing alternative. Not only are patient mutations and genetic background faithfully recapitulated in iPSCs, but neuronal differentiation protocols allow for the production of unlimited quantities of cells affected in the disease, providing a resource for biochemical and mechanistic studies, as well as modeling potential therapeutic strategies (15, 22) . However, two types of hurdles have been encountered. First, for some diseases, in vitro phenotypes of clear relevance to the human condition have proven hard to uncover. Second, even if differences are observed between iPSC derivatives from affected cases and healthy controls, it is essential to correct disease-causing mutations in iPSCs to demonstrate that the phenotype results from the disease gene rather than from other differences in genetic background.
In this study, we successfully generated GAN iPSCs from three GAN patients and differentiated them in vitro into spinal motor neurons (iPSC-MNs), a cell type strongly affected in patients. Strikingly, the GAN iPSC-MNs exhibit the intermediate filament protein accumulation characteristic of patients at early stages of the disease. Importantly, the GAN phenotypes can be rescued by gigaxonin replacement using either a lentiviral vector or stable transgenesis, demonstrating that the phenotype is caused by GAN mutation. GAN iPSCs therefore faithfully recapitulate key GAN phenotypes and will prove valuable tools for preclinical testing of gene replacement therapy and biochemical and genetic analysis of the disease process to identify additional therapeutic targets.
Results GAN is a rare neurodegenerative disease with limited access to patient samples. We were successful in obtaining skin biopsies from five patients who had either a confirmed mutation in GAN or a classical GAN phenotype in the absence of an identified mutation. To represent the clinical and genetic heterogeneity of the disease, samples were collected from GAN patients of different sex, age and mutation (Fig. 1A) . We generated iPSCs from skin fibroblasts by transduction with retroviral vectors encoding OCT4, SOX2, KLF4 and c-MYC as described (14) . All iPSC lines were assayed for formation of embryonic stem cell-like colonies with well-delineated phase-bright margins (Fig. 1B) , expression of nuclear and surface markers characteristic of human stem cells ( Fig. 1C and D) , karyotype ( Fig. 1E ) and viral transgene expression ( Fig. 1F and G) . Several iPSC lines were generated from each patient (Table 1 ; the line number refers to the GAN patient, and the letter refers to a particular iPSC clone). Lines from Patients 1 and 4 were excluded because of inadequate morphology of colonies, indicative of spontaneous differentiation or high persistent transgene expression ( Fig. 1F and G ), but those from Patients 2, 3 and 5 satisfied all criteria. One clone per Patient 2, 3 and 5 (iPSC lines 2E, 3X and 5L) was selected for subsequent detailed analysis.
As a first step toward analyzing the effects of the GAN mutations, we differentiated the three selected iPSC lines into motor neurons (iPSC-MNs)-as motor neuron axons are strongly affected in patients-using a 28-day embryoid body-based protocol (15) that generates iPSC-MNs with ∼20-30% efficiency ( Fig. 2A) . Microtubule-associated protein 2 (MAP2)-positive cells generated from GAN iPSCs exhibited typical neuronal morphology (Fig. 2E ) and expressed motor neuron markers HB9 and ISL1 at similar levels to a control iPSC line 18c (15) (Fig. 2F and data not shown) . In addition, GAN neurons cultured for 12 days formed dense networks of processes and exhibited abundant spontaneous Ca 2+ transients, demonstrating that they are functionally active (Fig. 2G) . Patients with GAN have low, sometimes undetectable levels of gigaxonin protein (4) . Similarly marked reductions were seen in fibroblasts, iPSCs and iPSC-derived neuronal cultures for all patients (Fig. 2B , C and D, respectively), including Patient 5, whose mutations remain to be identified. Therefore, deficits in gigaxonin levels do not impact the differentiation capacity of iPSCs to spinal motor neurons.
We next asked whether GAN iPSC-derived neurons display any of the cytoskeletal defects seen in patients, initially using the mixed spinal neuronal cultures generated by our protocol. One study found that a peripheral nerve from a GAN patient contained 2-fold more NF-L than a control sample, whereas levels of neurofilament medium chain (NF-M) and neurofilament Human Molecular Genetics, 2015, Vol. 24, No. 5 | 1421 heavy chain (NF-H) were unchanged (23) . In a striking parallel, iPSC-neurons from all GAN patients expressed levels of NF-L that were 3-to 4-fold higher than controls ( Fig. 3B, H ; P = 0.049, 0.026 and 0.015 for GAN2E, 3X and 5L, respectively), whereas levels of NF-M were comparable with control ( Fig. 3C, I ; P = 0.26, 0.33 and 0.16). Levels of NF-H could not be measured due to lack of a reliable signal on western blot (WB). These findings are also in agreement with reports of an increased abundance of the NF-L subunits in GAN mouse models at later time points, while NF-M and NF-H are less affected (11, 13) . Western blot analysis further revealed an increase in the neuronal intermediate filament protein peripherin (PRPH) in differentiated GAN iPSCs ( Fig. 3A and G; P = 0.038, 0.016 and 0.034) as has been reported in the mouse Gan Δex1/Δex1 model (11) . As in mouse models (11) , the elevation of NF-L and PRPH did not reflect accumulation of mRNA (P > 0.05, Supplementary material, Fig. S1 ). Human GAN neurons therefore exhibit a selective accumulation of neural intermediate filament proteins that mimics the situation in vivo. Interestingly, vimentin levels in iPSC-neurons appeared not to differ significantly between patients and control ( Fig. 3D and J; P = 0.23, 0.45 and 0.49). Although vimentin forms aggregates in fibroblasts derived from GAN patient skin biopsies, its overall levels were not reported to be elevated (24) (25) (26) . Similarly, GAN In the developing nervous system, PRPH is selectively enriched in spinal motor neurons and sensory neurons, the cell types primarily affected in GAN patients (27) . We therefore focused our analysis on PRPH as a potential source of cell-typespecific GAN pathology. To determine whether the intermediate filament phenotypes observed in these mixed cultures reflected changes in iPSC-MNs themselves, we studied the subcellular localization of PRPH at the level of individual cells. In identified ISL1
+ iPSC-MNs, we observed perinuclear accumulation of PRPH immunoreactivity in GAN ( Fig. 3P ) but not in control (Fig. 3N) cultures. This is reminiscent of the perinuclear intermediate filament aggregates seen in patient fibroblasts (28) and the neuronal intermediate filament accumulations seen in the giant axons of patients (7) . In contrast, no change in MAP2 intensity or localization was apparent ( Fig. 3M and O). To better characterize these perinuclear accumulations, we took high magnification single optical plane confocal images ( Fig. 3Q-T) . Both PRPH and NF-L colocalize in the perinuclear aggregates and while filamentous structures were detected by immunocytochemistry at the periphery of the aggregates light microscopy did not provide sufficient resolution to determine whether the proteins within the cores of the aggregates have filamentous or disorganized structure.
To quantify the observed differences in protein accumulation, we measured intensity of MAP2 and PRPH immunostaining on Neuralization was induced using SB and LDN. Cells were caudalized and ventralized, using retinoic acid and SAG/purmorphamine, respectively (see 'Materials and Methods' for details). After 28 days of differentiation, embryoid bodies (EBs) were dissociated and MNs were plated. Cells were lysed for WB on Day 0, and fixed for ICC a cell-by-cell basis. The distribution of MAP2 intensities did not differ between the two genotypes (Fig. 3U ). In contrast, PRPH was increased in GAN iPSC-MNs: only <30% of control neurons have PRPH intensities >2000 units whereas for GAN neurons this figure is >70% (Fig. 3V ). Using the non-parametric Kolmogorov-Smirnov test (two-sample K-S test), the P-value for MAP2 differences between GAN and control is 0.6, whereas for PRPH P < 0.001. Thus the GAN genotype is associated with a selective increase of PRPH levels in iPSC-MNs. Phenotypes reported in iPSC-derived cell types can potentially reflect inter-individual genetic differences unrelated to disease. It was therefore critical to determine whether the phenotypes observed thus far reflected direct effects of the loss of function mutation in GAN gene. We constructed lentiviral vectors expressing myc-GAN or green florescent protein (GFP) (as a control) under the control of the strong phosphoglycerate kinase-1 (PGK) promoter and used them to transduce the GAN2E and control iPSC-MN cultures ( Fig. 4A and B) . To measure overall levels of PRPH and control cytoskeletal proteins in the culture, cell extracts were analyzed by densitometry of WBs in three independent experiments ( Fig. 4C and E) . Despite the high levels of gigaxonin generated by the strong PGK promoter, total numbers of PRPH-positive cells were indistinguishable in control and experimental conditions (Fig. 4D) demonstrating that gigaxonin overexpression is not neurotoxic. Importantly, the elevated PRPH levels in GAN cells were significantly reduced ( Fig. 4E ; 2.9 ± 0.5-fold compared with GFP-infected cells; n = 3; mean ± SEM, P = 0.01) whereas levels of tau and α-tubulin were not significantly affected (1.1 ± 0.2-fold for tau, P = 0.36).
We next examined rescue of the PRPH phenotype on a cell-bycell basis. Cultures were stained for the virus (either GFP or myc) as well as for PRPH and MAP2 (Fig. 4F-K) . Uninfected cultures displayed a significant increase in PRPH levels in GAN MNs as compared with controls (Fig. 4L ). This was rescued by overexpression of gigaxonin ( Fig. 4M ; P < 0.0001). Seven days post-infection, PRPH staining was reduced to control levels in GAN iPSC-MNs infected with myc-GAN virus ( Fig. 4M ; P < 0.0001 for GAN2E + GFP as compared with the other three conditions). The reduction was observed selectively in those neurons that were infected by the virus (Fig. 4J, arrowhead) . Thus, restoration of gigaxonin at a time point at which intermediate filament accumulation is already apparent can revert the pathological accumulation of PRPH without causing iPSC-MN loss.
Because the PGK promoter leads to levels of gigaxonin that are >15-fold greater than those of the endogenous protein, we sought to confirm these results in a more physiologically relevant context by using stable expression of gigaxonin at lower levels. GAN3X iPSCs were nucleofected with a construct for expression of EF1α::FLAG-gigaxonin as well as puromycin resistance (Fig. 5A and B) . Approximately 1 week after nucleofection, cultures were exposed to puromycin, and ∼1 week later resistant clones were picked and expanded for test differentiations. Of the ∼24 clones picked, three derived from GAN3X expressed FLAG-gigaxonin (Fig. 5C , D and E; individual clones are indicated by their clone number).
Positive clones were identified by IF, WB and qPCR and were shown to generate iPSC-MNs with unaltered efficacy (Fig. 5C and data not shown). Rescue clones expressed FLAG-gigaxonin at variable levels of transgene expression (Fig. 5D and E, upper band in GIG WB). GAN3X clone 1 expressed slightly higher levels of gigaxonin as compared with 18c (1.18-fold, all values normalized to 18c), and clones 11 and 20 expressed at lower levels (0.89 and 0.63, respectively) but still above the expression level of the parent GAN3X line (0.60). Interestingly, expression of FLAG-GIG seemed to stabilize endogenous gigaxonin (Fig. 5E , lower band in GIG WB). PRPH levels were corrected in the rescue lines as compared with the parental line ( Fig. 5F and G; two to three independent experiments for each clone; P < 0.05 for all GAN3X rescue clones compared with the parental line). Therefore, accumulated PRPH in GAN iPSC-MNs is remarkably sensitive to gigaxonin levels and its level can be effectively corrected by virally delivered gigaxonin, raising a hope for therapeutic effects of gene therapy in GAN.
Discussion
iPSC-based models of human familial diseases offer promise for accelerated characterization of pathologic pathways underlying the diseases and for the ultimate development and validation of new therapeutic strategies. Here, we outline such an approach for GAN, an incurable disease-causing progressive neurodegeneration of sensory and motor neural circuits. We report successful derivation of iPSCs from the fibroblasts of three GAN patients with unique mutations in the GAN gene. We provide evidence that GAN iPSCs exhibit normal ability to differentiate into spinal motor neurons. Importantly, GAN-specific pathological phenotypes can be observed in GAN iPSC-MNs at early time points in culture. Moreover, replacement of gigaxonin in cultured cells using lentiviral delivery or stable transfection reversed accumulation of PRPH. This suggests that delivery of the gigaxonin protein to cells that already exhibit signs of pathology might be sufficient to stop or perhaps even reverse the course of disease in GAN patients.
Many studies using iPSC models from patients and controls have left open the question as to whether the observed differences are true disease-relevant phenotypes or rather reflect inter-individual genetic variability not directly related to disease (29) . To directly address this question, we used genetic rescue of the disease-causing mutation in iPSC lines to create isogenic pairs of lines ideally suited for disease modeling. We found that replacement of gigaxonin in cultured human iPSC-MNs completely reverses intermediate filament protein accumulation. Therefore, we have defined a gigaxonin-dependent phenotype that likely represents a key early step in the disease process. Moreover, our iPSC model is the first cell-based model of this disease that recapitulates intermediate filament protein accumulation (rather than aggregation alone, as seen in patient fibroblast models). One possible explanation is that we studied motor neurons, one of the principal cell types affected in the disease, rather than undifferentiated skin fibroblasts.
Therapy for GAN has been focused for some while on replacement of the missing gigaxonin. Encouragingly, our study is in agreement with in vivo data that this approach may reverse the disease process and clear PRPH aggregates as has been recently shown in a mouse model of GAN (30) . Although questions of safety and feasibility remain to be addressed, our study provides neurons were stained for PRPH and NF-L 7 days post-dissociation and imaged using confocal microscopy. Asterisk indicates location of nucleus. Scale bar, 25 µ. (U and V) PRPH and MAP2 intensity levels in the cell body region of individual control and GAN2E MNs (>55 per condition) were measured using MetaMorph and plotted as cumulative frequency of two independent experiments using the Kolmogorov-Smirnov non-parametric test. The P values are 0.598 for the data shown in (S) and <0.0001 for the data shown in (T). data relevant to the safety, timing and dosage of gigaxonin at several levels. First, because gigaxonin is believed to activate proteasomal degradation, one concern was that overexpression of the protein might be toxic. However, patient-derived iPSC-MNs tolerated levels of gigaxonin ∼15-fold greater than normal. Second, we observed that gigaxonin overexpression is still effective when initiated after the onset of intermediate filament protein accumulation, suggesting that delivery to cells that already exhibit signs of pathology may stop or even reverse disease progression. Lastly, because gigaxonin is quite effective even at low levels, it may be Human Molecular Genetics, 2015, Vol. 24, No. 5 | 1427 possible to attain effective concentrations even in cell types that are difficult to transduce. In summary, GAN is one of only a few human diseases for which iPSCs faithfully recapitulate a specific biochemical pathology observed in patients. Using this model, we demonstrate reversal of an existing pathological phenotype by gigaxonin overexpression, providing proof of principle for gene replacement therapy for this devastating disease. The iPSC-based model of GAN we have developed has the dual potential to significantly accelerate preclinical studies while serving as a tool for the discovery and validation of new therapeutic approaches.
Materials and Methods

Isolation of fibroblasts from patients with GAN
Dermal fibroblasts from five patients with GAN were obtained through skin biopsy. All samples were taken prior to the study, and written informed consent of the parents of patients was obtained for the identifiable samples according to the protocol approved by the Internal Research Board of Columbia University. Three other samples were sent to Columbia University as deidentified tissue samples. The only demographic data collected was age, date of birth and the mutation, if known.
Cell culture
Human GAN and control fibroblasts were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum and penicillin/streptomycin at 37°C with 5% CO 2 . All fibroblast samples were tested for mycoplasma, and positive GAN fibroblasts (GAN1 and 3) were treated with Plasmocin (1 : 5000, InvivoGen) for 2 weeks, at which point they were retested after 1 week in antibiotic-free media and determined to be cleared of the infection. GAN and control iPSCs were maintained on irradiated mouse embryonic fibroblasts (MEFs) in Human embryonic stem cell medium (HuESM) [DMEM/F12 supplemented with 20% knockout serum replacement, non-essential amino acids (NEAA), -glutamine, β-mercaptoethanol (BME) and 20 ng/ml of basic fibroblast growth factor (bFGF)]. Media were changed every 24 h, and lines were passaged using dispase (Gibco, 1 mg/ml in HuESM for 30 min at 37°C).
GAN iPSC derivation
Twenty thousand fibroblasts were infected in 1 ml of HuESM in 1-well of a 6-well plate with a combination of OCT4, SOX2, cMYC and KLF4-containing murine leukemia retroviruses as described previously (31) . Cells were incubated with virus in 1 ml of HuESM for 24 h before the medium was supplemented with 1 ml of fibroblast medium to allow cells to recover. On Day 3, the medium was changed to HuESM with the small molecule compounds (32) PD0325901 (0.5 μ, Stemgent), SB431542 (2 μ, Stemgent) and Thiazovivin (0.5 μ, Stemgent). Approximately 1 week later, fluorescence-activated cell sorting was used to isolate enriched populations of CD13 NEG SSEA4 POS Tra-1-60 POS cells. These were sorted as single cells onto MEFs in 6-well plates, and iPSC colonies were manually picked based on morphology within 2-4 weeks.
Karyotyping
Karyotype analysis was performed by Cell Line Genetics, LLC.
Quantitative reverse transcriptase polymerase chain reaction
Total RNA was isolated using Trizol LS (Invitrogen). One microgram was treated with DNase (Invitrogen) and was subsequently used to synthesize cDNA with iScript (Bio-Rad). Quantitative RT-PCR was then performed using SYBR green (Bio-Rad) and the iCycler system (Bio-Rad). Quantitative levels for all genes were normalized to endogenous β2 microglobulin (B2M) (for iPSC characterization) or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (for all other experiments). For pluripotency genes, levels were expressed relative to the levels in human ES line HUES42. For viral genes, levels were expressed relative to the levels in HEK293 cells infected with the reprogramming viruses for 2-3 days. Standard curves were run to ensure equal efficiency of all primers, and RNA from HEK293 cells transfected with the plasmids encoding the transgenes was used as a positive control for viral transgene detection. Primer sequences are available upon request. Data were analyzed using the comparative quantitation by the 2 ÀΔΔCT equation:
, where ΔC T is the threshold cycle (C T ) value of the housekeeping gene (B2M or GAPDH) subtracted from the C T value of the target gene.
Immunohistochemistry
Pluripotency marker stains of iPSCs were performed after fixation overnight in 4% paraformaldehyde (PFA) at 4°C as previously described ( 
Microscope image acquisition
Images were acquired on a fully automated Zeiss Observer Z1 
Quantitative image analysis
Quantitative image analysis of differentiated neuronal cultures was performed using the Multi-Wavelength Cell Scoring module in MetaMorph (Molecular Devices) software. In brief, intensity thresholds were set (blinded to sample identity) to selectively identify positive cells that displayed an unambiguous signal intensity above local background. These parameters were used on all samples, and only minimally adjusted for different staining batches as necessary. Script and parameter files were available upon request. Where stated, cells were visually identified and average cell body intensity measured by drawing a region of interest that encompassed the cell body. Brightness and contrast of each grayscale channel were adjusted to improve clarity.
Protein isolation and western blot analysis
Cells were isolated, suspended in RIPA lysis buffer supplemented with protease and phosphatase inhibitor cocktail (Roche), triturated and centrifuged at 10 000g for 15 min at 4°C. Then, 1-10 μg of total protein was separated on 10% sodium dodecyl sulfatepolyacrylamide gels, transferred to a nitrocellulose membrane and probed with various primary antibodies, followed by horseradish-peroxidase-conjugated secondary antibody (1 : 5000-10 000, for mouse or rabbit primaries, respectively; Invitrogen), and visualized using ECL chemiluminescence (33 For viral experiments, the membranes were stripped and re-probed for NF-L. Membranes were washed in PBS Tween, incubated for 15 min at room temperature with stripping buffer, followed by 7 min at 37°C. They were then washed for 1 h in PBS Tween, blocked and probed with appropriate secondaries to confirm that the original signal was removed before reprobing.
Motor neuron differentiation of GAN and control iPSCs
Pluripotent stem cell colonies were treated with dispase (1 mg/ ml) to separate colonies from feeder cells, washed and then triturated to five to 10 cell clumps and seeded in low-adherence dishes in HuESM medium with 20 ng/ml of bFGF, SB431542 (10 μ, SIGMA), LDN193189 (0.2 μ, Stemgent) and Y-27632 (20 μ Ascent) for the first 2 days. At Day 3, embryoid bodies (EBs) were switched to a neural induction medium (DMEM/F12 with -glutamine, NEAA, penicillin/streptomycin, heparin (2 μg/ ml), N2 supplement (Invitrogen), brain-derived neurotrophic factor (BDNF) (10 ng/ml) and ascorbic acid (0.4 μg/ml). At Day 7, retinoic acid (1 µ, Sigma), SAG (1 μ, Calibiochem smoothened agonist 1.3), and purmorphamine (1 μ, Stemgent) were added. At Day 17, the base medium was changed to Neurobasal (Invitrogen), with all previous factors and with the addition of 10 ng/ml each of BDNF, glial derived neurotrophic factor and ciliary neurotrophic factor (R&D), plus B-27 supplement (1 : 50, Invitrogen). At Day 28, EBs were then dissociated with 0.05% trypsin (Invitrogen) and plated onto poly-lysine laminin-coated 96-well plates or 6-well plates at 10 000 or 1 million cells/well, respectively. Plated neuron cultures were cultured in the same medium with the addition of 25 μ BME (Millipore) and 25 μ glutamic acid (Sigma).
Where indicated, cell division was inhibited with 5-fluoro-2-deoxyuridine (UFdU, 1 μ, Sigma).
Statistical analysis
All quantitative data were analyzed using Microsoft Excel or GraphPad. The Kolmogorov-Smirnov test was used to compare the probability distribution of the PRPH intensities of GAN and control MNs using an XLSTAT macro in Excel (Fig. 3S and T) . Non-Gaussian sample groups were compared with a KruskalWallis test using GraphPad Software (Fig. 4H ). Student's t-test was used to compare individual GAN patients with control (Figs 3G-L, 4L, M and 5F).
Calcium imaging
For epifluoresence microscopy, cells were loaded with 3 μ Fluo-4. Images were acquired at ∼2 Hz. Image analysis was performed using ImageJ software and custom macros. Ca 2+ transients were determined from regions of interest encompassing the soma of individual cells, using raw pixel intensities.
Viral rescue experiments
Myc-tagged human gigaxonin was cloned from a plasmid courtesy of Dr Steven Gray (UNC). NSC34 cells were infected with 10-fold dilutions of viral supernatant. Four days later, cells were fixed and stained for myc or GFP, and quantified with MetaMorph. The transducing units per microliter were determined from the slope of the linear regression. For subsequent experiments with MNs, virus was added at 0.22-0.27 TU/cell. For WB and intermediate filament data, MNs were infected 12 days after plating and were collected and fixed 7-9 days later.
Nucleofection of iPSC lines
For rescue lines, the plasmid used was EF1α::FLAG-gigaxonin, which contains a puromycin-resistance cassette. iPSC lines were dissociated into single cells using trypsin and incubated with Y-27632 as single cells for 1 h before nucleofection. Cells were nucleofected using the Amaxa Nucleofector ® II (5 million cells and 5 μg linearized plasmid). Cells were then plated on puromycin-resistant MEFs and allowed to form small colonies before beginning antibiotic selection. After 10 or more days of selection, large colonies were picked and expanded for further characterization.
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